Palisade Bio (NASDAQ:PALI – Get Free Report) was upgraded by equities researchers at Maxim Group from a “hold” rating to a “buy” rating in a research report issued on Friday, Benzinga reports. The brokerage presently has a $1.50 target price on the stock. Maxim Group’s target price would indicate a potential upside of 147.93% from the company’s previous close.
Palisade Bio Stock Up 15.7 %
Shares of PALI opened at $0.61 on Friday. Palisade Bio has a 52-week low of $0.50 and a 52-week high of $8.54. The company has a market capitalization of $5.58 million, a PE ratio of 0.04 and a beta of 1.60. The stock has a fifty day simple moving average of $0.58 and a two-hundred day simple moving average of $1.16.
Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its earnings results on Thursday, November 9th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.09). As a group, equities analysts anticipate that Palisade Bio will post -1.82 earnings per share for the current fiscal year.
Institutional Trading of Palisade Bio
About Palisade Bio
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.
- Five stocks we like better than Palisade Bio
- Stock Market Sectors: What Are They and How Many Are There?
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 11/13 – 11/17
- Upcoming IPO Stock Lockup Period, Explained
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.